Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19053808 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19053784 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19017356 | MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19012978 | VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOF | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19007447 | METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 19000472 | BETACORONA VIRUS mRNA VACCINES | December 2024 | June 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18981054 | ANTI-HUMAN NR1 ANTIBODY DERIVATIVE | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18964018 | Alpha-herpesvirus Insensitive Monoclonal Cell Strain, and Preparation Method Therefor and Use Thereof | November 2024 | April 2025 | Allow | 4 | 1 | 1 | No | No |
| 18955940 | PREPARATION METHOD AND APPLICATION OF NANOBODY TARGETING DENGUE VIRUS NS1 PROTEIN | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18948648 | INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18865515 | FUSION PROTEIN AND USE THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 0 | No | No |
| 18941809 | NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS | November 2024 | May 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18936852 | METHODS OF FABRICATING CARRIERS FOR TARGETED DELIVERY TO A HOST | November 2024 | April 2025 | Allow | 5 | 1 | 0 | No | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18929510 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18927301 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18923470 | BIOMOLECULE DETECTION METHOD USING DIFFUSION ORDERED SPECTROSCOPY | October 2024 | April 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18915537 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | October 2024 | May 2025 | Allow | 7 | 0 | 1 | No | No |
| 18909225 | METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODY | October 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18903289 | METHOD FOR CONSTRUCTING gE PROTEIN-DELETED PSEUDORABIES VIRUS STRAIN USING ADENINE BASE EDITOR AND USE THEREOF | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18901182 | ANTIBODY TARGETING B CELL MATURATION ANTIGEN AND RELATED PRODUCTS THEREOF AND MEDICAL APPLICATIONS | September 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18899511 | METHOD FOR AMELIORATING OR AVOIDING THE ADVERSE EFFECTS OF EXOGENOUS GONADOTROPINS ON REPRODUCTIVE PERFORMANCE | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18896718 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | September 2024 | April 2025 | Allow | 7 | 2 | 1 | Yes | No |
| 18896286 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | September 2024 | December 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18892253 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING PTK7 | September 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18887496 | APPLICATION OF HIGH MANNOSE GLYCAN BINDING PROTEINS AND COMPLEX GLYCAN BINDING PROTEINS | September 2024 | June 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18882795 | RAPID DETECTION METHOD FOR ABRIN TOXIN | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18830877 | ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18829320 | PROTEIN SCAFFOLD CAPABLE OF CARRYING RADIOACTIVE SIGNALS AND APPLICATION IN ANTIBODY DETECTION | September 2024 | May 2025 | Allow | 8 | 1 | 0 | No | No |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18823573 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | September 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18823422 | ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOF | September 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18821708 | METHODS OF CROSSLINKING IgG | August 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18817109 | ANTI-IL-18BP ANTIBODIES | August 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18808126 | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) METHOD AND MONOCLONAL ANTIBODY FOR GIANT PANDA RELAXIN-3 (RLN3) | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18807825 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18804738 | INTERLEUKIN 21 VARIANTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18801895 | ESTABLISHMENT AND SUSPENSION ACCLIMATION OF CRFK ADHERENT CELL LINE, AND ITS APPLICATION | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18801071 | NUCLEIC ACID VACCINES | August 2024 | June 2025 | Abandon | 10 | 1 | 0 | Yes | No |
| 18800440 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18801143 | NUCLEIC ACID VACCINES | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18801174 | NUCLEIC ACID VACCINES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18798779 | RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATION | August 2024 | May 2025 | Allow | 9 | 1 | 0 | No | No |
| 18792611 | COXSACKIEVIRUS B4 STRAIN AND APPLICATION THEREOF | August 2024 | May 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18792080 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | August 2024 | May 2025 | Abandon | 9 | 1 | 0 | Yes | No |
| 18790657 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18790955 | ANTI-GPRC5D ANTIBODIES AND COMPOSITIONS | July 2024 | December 2024 | Allow | 4 | 0 | 1 | No | No |
| 18789799 | RAPID DETECTION METHOD FOR RICIN TOXIN | July 2024 | December 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18788938 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18783156 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | July 2024 | June 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18779961 | PREFUSION-STABILIZED HMPV F PROTEINS | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18777836 | C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOF | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18773461 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | July 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18770056 | POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASES | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18769708 | ASSAY METHOD OF ANTIBODY | July 2024 | March 2025 | Allow | 8 | 1 | 0 | No | No |
| 18762296 | BETACORONAVIRUS mRNA VACCINES | July 2024 | October 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18762372 | BETACORONAVIRUS RNA VACCINES | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18762384 | BETACORONAVIRUS RNA VACCINES | July 2024 | October 2024 | Allow | 3 | 2 | 0 | Yes | No |
| 18751599 | BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18752739 | METHOD FOR DETECTING AFLATOXIN B1 CONTENT USING FLUORESCENCE ANALYSIS BASED ON OPTICAL SECTIONING | June 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18749700 | COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUS | June 2024 | April 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18750971 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18722997 | MAGNETIC CHEMILUMINESCENCE IMMUNOASSAY KIT BASED ON BIFUNCTIONAL FUSION PROTEIN FOR MYCOTOXINS, AND USE THEREOF | June 2024 | March 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18720291 | IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18742986 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18738696 | VACCINE MOLECULES | June 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18738824 | TRANSTHYRETIN ANTIBODIES AND USES THEREOF | June 2024 | March 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18737465 | BCG AND IL-15 BASED MOLECULES | June 2024 | March 2025 | Allow | 9 | 3 | 0 | No | No |
| 18737455 | IL-15-BASED MOLECULES WITH ANTI-CD20 ANTIBODY AND METHODS OF USE | June 2024 | February 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18734010 | ADOPTIVE CELLULAR THERAPY | June 2024 | May 2025 | Allow | 12 | 1 | 0 | No | No |
| 18734520 | MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY | June 2024 | January 2025 | Allow | 8 | 0 | 0 | No | No |
| 18732612 | METHOD FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY PATHOGEN-ASSOCIATED MOLECULAR PATTERN | June 2024 | June 2025 | Abandon | 12 | 1 | 1 | No | No |
| 18680187 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSES | May 2024 | May 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18731059 | METHOD OF ASSESSING RISK OF PML | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18680137 | METHODS AND CONSTRUCTS FOR PRODUCTION OF LENTIVIRAL VECTOR | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18731146 | HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF | May 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18679187 | Advanced Avatar Dendritic Cells | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18679192 | COMPOSITION COMPRISING AFLIBERCEPT AND A VARIANT THEREOF, AND RELATED METHODS AND USES | May 2024 | November 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18675059 | CHIKUNGUNYA VIRUS (CHIKV) VIRUS-LIKE PARTICLES (VLPS) COMPRISING THE C, E1, AND E2 STRUCTURAL PROTEINS | May 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
| 18674179 | Bead-based analysis of a sample | May 2024 | January 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18671801 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18668571 | USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALS | May 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18665920 | Compositions and Methods for Antigen Targeting to CD180 | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18662554 | METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEIN | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18662436 | CHIMERIC INFLUENZA VACCINES | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18661576 | TUBERCULOSIS DETECTION KIT | May 2024 | January 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18660609 | PORCINE EPIDEMIC DIARRHEA VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROM | May 2024 | February 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18656957 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | May 2024 | April 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18656092 | ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF | May 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18656236 | IL23R BINDING MOLECULES AND METHODS OF USE | May 2024 | March 2025 | Abandon | 10 | 0 | 1 | No | No |
| 18654901 | COXSACKIEVIRUS A6 STRAIN CVA6-KM-J33 AND USE THEREOF | May 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18650566 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650526 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650552 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650778 | EXTRACELLULAR VESICLE DERIVED MASP-2 DIRECTED CANCER TREATMENT METHODS | April 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18649981 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | April 2024 | January 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18649467 | A549 HOST CELLS COMPRISING A RECOMBINANT ONCOLYTIC ADENOVIRUS WITH MODIFIED E1A CANCER-SPECIFIC PROMOTER | April 2024 | December 2024 | Allow | 8 | 0 | 0 | No | No |
| 18648190 | STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF | April 2024 | December 2024 | Allow | 7 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1670.
With a 33.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1670 is part of Technology Center 1600. This group has examined 28,921 patent applications in our dataset, with an overall allowance rate of 72.4%. Applications typically reach final disposition in approximately 29 months.
Applications in Group 1670 receive an average of 1.85 office actions before reaching final disposition. The median prosecution time is 29 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.